Idarucizumab

Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.
Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.
It was approved for medical use in the United States and in the European Union in 2015.
Society and culture.
Names.
Idarucizumab is the International nonproprietary name (INN). The description was updated in 2016. Idarucizumab is the United States Adopted Name (USAN).